Adezunap

Phase 3Small molecule

AApurano Pharmaceuticals GmbH

Adezunap is one of 124 small molecule programs targeting Peripheral Neuropathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

123

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peripheral NeuropathyActive, not recruiting

Chronic PainActive, not recruiting

Diabetic PolyneuropathyActive, not recruiting

Back PainActive, not recruiting

Peripheral NeuropathyPhase 3

Active, not recruiting

Chronic PainPhase 3

Active, not recruiting

Diabetic PolyneuropathyPhase 3

Active, not recruiting

Back PainPhase 3

Active, not recruiting

Competition

Competitive Landscape

193 competitors in Chronic Pain

#DrugCompanyPhaseTrials

Neurontin

VViatris Specialty LLC

Phase 3

3 2

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Phase 3

1 3

Buprenorphine IV

PPurdue Pharma LP

Phase 3

1 4

Adezunap

AApurano Pharmaceuticals GmbH

Phase 3

2 5

Naloxone Hydrochloride

PPurdue Pharma LP

Phase 3

2 6

BEMA Fentanyl

BBioDelivery Sciences International

Phase 3

1 7

MS Contin

Merck & Co.

Preclinical

3 8

Cymbalta

Alnylam Pharmaceuticals

Preclinical

2 9

Dayvigo

Eisai

Preclinical

1 10

Ultram

Haisco Pharmaceutical Group Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic pain2 trials

Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis

Unknown status·AApurano Pharmaceuticals GmbH·Phase 3·NCT06071949·558 enrolled

Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis

Unknown status·AApurano Pharmaceuticals GmbH·Phase 3·NCT06072001·558 enrolled

Peripheral Neuropathy2 trials

Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy

Unknown status·AApurano Pharmaceuticals GmbH·Phase 3·NCT06071936·558 enrolled

Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy

Unknown status·AApurano Pharmaceuticals GmbH·Phase 3·NCT06071988·558 enrolled

Back pain2 trials

Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain

Unknown status·AApurano Pharmaceuticals GmbH·Phase 3·NCT06072560·558 enrolled

Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain

Unknown status·AApurano Pharmaceuticals GmbH·Phase 3·NCT06071962·558 enrolled

Diabetic Polyneuropathy2 trials

Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy

Unknown status·AApurano Pharmaceuticals GmbH·Phase 3·NCT06071975·558 enrolled

Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy

Unknown status·AApurano Pharmaceuticals GmbH·Phase 3·NCT06072573·558 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Adezunap. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Adezunap compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Adezunap. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Apurano Pharmaceuticals GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AApurano Pharmaceuticals GmbH

Adezunap

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic pain2 trials

Peripheral Neuropathy2 trials

Back pain2 trials

Diabetic Polyneuropathy2 trials

References

Drug Info

Quick Facts

Related News